Serena A Morrison, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 158 Northport Ave, Belfast, ME 04915 Phone: 207-338-2571 Fax: 207-338-3810 |
Dr. Lyndon W Morgan, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 158 Northport Ave, Belfast, ME 04915 Phone: 207-338-2571 Fax: 207-338-3810 |
News Archive
Western States Biopharmaceuticals, Inc., a privately-held biotechnology company focusing on the development of novel therapies to treat inflammatory disease, and the University of Colorado announced today that they have entered into a licensing agreement for approaches to inhibiting newly discovered T cell Cytokine Inducing Surface Molecules, or TCISM autoimmune disease drug discovery targets.
Speaking at the American Society for Microbiology's (ASM) Biodefense and Emerging Diseases Research meeting in Washington, D.C., on Wednesday, Ron Fouchier, the leader of the team at Erasmus Medical Center in the Netherlands that genetically altered the H5N1 bird flu virus, making it transmissible among ferrets and "touching off public fears of a pandemic, said that the virus he created was neither as contagious nor as dangerous as people had been led to believe, prompting the United States government to ask that the experiments be re-evaluated by a government advisory panel that recommended in December that certain details of the work be kept secret and not published," the New York Times reports.
The Department of Health and Human Services has mailed out a third round of $250 checks to help seniors who enter the Medicare Part D coverage pay gap for prescription drugs, WCAX [in Vermont] reports. "The one-time payment aims to close a gap in coverage for prescription medication. The rebates will go to about 9,000 Vermonters whose out-of-pocket expenses already total more than $940 for the year" (8/11).
Rebiotix Inc. today announced that U.S. Food and Drug Administration has designated its lead Microbiota Restoration Therapy (MRT) RBX2660 as a Breakthrough Therapy for the treatment of recurrent Clostridium difficile (C diff) infection, a challenging to treat gastrointestinal (GI) infection that causes 29,000 deaths in the U.S. annually.
Surefire Medical, Inc., developer of a new class of infusion systems designed to maximize direct-to-tumor drug delivery, announced today that the company has received 510(k) FDA clearance and the CE Mark for its enhanced line of Surefire Guiding Catheters used in radioembolization and chemoembolization procedures.
› Verified 7 days ago